Riluzole, a glutamate release inhibitor, and motor behavior

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 358, Issue 2, 1998, Pages 181-190

  Kretschmer, Beate D ^a   Kratzer, Ulrich ^a   Schmidt, Werner J ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Ataxia; Catalepsy; Glutamate; Glutamate inhibitor; Locomotion; NMDA; Riluzole; Stereotypy

Indexed keywords

1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 4 AMINOBUTYRIC ACID; CYCLOSERINE; GLUTAMATE RECEPTOR; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID; RILUZOLE; SODIUM CHANNEL;

ANIMAL EXPERIMENT; ARTICLE; ATAXIA; BEHAVIOR; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG EFFECT; LOCOMOTION; MOTOR ACTIVITY; NEUROPROTECTION; NONHUMAN; RAT;

EID: 0031680551     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00005241     Document Type: Article

References (56)

1. Albers GW, Atkinson RP, Kelly RE, Rosenbaum DM (1995) Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrophan in patients with acute stroke. Stroke 26:254-258
2. Benazzouz A, Boraud T, Dubedat P, Boireau A, Stutzmann JM, Gross C (1995) Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study. Eur J Pharmacol 284:299-307
3. Benismon G, Lacomblez L, Meininger V (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 330:585-591
4. Bennett DA, Bernard PS, Amrick CL, Wilson DE, Liebman JM, Hutchinson AJ (1989) Behavioral pharmacological profile of CGS 19755, a competitive antagonist at N-methyl-D-aspartate receptors. J Pharmacol Exp Ther 250:454-460
5. Bigge CF (1993) Structural requirements for the development of potent N-methyl-D-aspartic acid (NMDA) receptor antagonists. Biochem Pharmacol 45:1547-1561
6. Boireau A, Dubedat P, Bordier F, Peny C, Miquet J-M, Durand G, Meunier M, Doble A (1994a) Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice. Neuroreport 5:2657-2660
7. Boireau A, Miquet J-M, Dubedat P, Meunier M, Doble A (1994b) Riluzole and experimental parkinsonism: partial antagonism of MPP+-induced increase in striatal extracellular dopamine in rats in vivo. Neuroreport 5:2157-2160
8. Boldry RC, Kelland MD, Engber MD, Chase TM (1993) NBQX inhibits AMPA-induced locomotion after injection into the nucleus accumbens. Brain Res 600:331-334
9. Bubser M, Keseberg U, Notz PK, Schmidt WJ (1992) Differential behavioural and neurochemical effects of competitive and non-competitive NMDA receptor antagonists in rats. Eur J Pharmacol 229:75-82
10. Bubser M, Tzschentke T, Hauber W (1995) Behavioural and neurochemical interactions of the AMPA antagonist GYKI 52466 and the non-competitive NMDA antagonist dizocilpine in rats. J Neural Transm 101:115-126
11. Bubser M, Zadow B, Kronthaler UO, Felsheim U, Rueckert NGH, Schmidt WJ (1997) Behavioural pharmacology of the non-competitive NMDA antagonists dextrophan and ADCI: relations between locomotor stimulation, anti-cataleptic potential and forebrain dopamine metabolism. Naunyn Schmiedebergs Arch Pharmacol 355:767-773
12. Carlsson M, Carlsson A (1989) The NMDA antagonist MK 801 causes marked locomotor stimulation in monoamine-depleted mice. J Neural Transm 75:221-226
13. Carter AJ (1994) Many agents that antagonize the NMDA receptor-channel complex in vivo also cause disturbance of motor coordination. J Pharmacol Exp Ther 269: 573-580
14. Clineschmidt BV, Martin GE, Bunting PR (1982) Anticonvulsant activity of (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic, and apparent anxiolytic properties. Drug Dev Res 2:123-134
15. Cools AR, Peeters BWMM (1987) Behavioral function of neostriatal glutamate and its interaction with dopamine. Neurosci Res Commun 1:47-55
16. Danysz W, Essman U, Bresink I, Wilke R (1994) Glutamate antagonists have different effects on spontaneous locomotor activity in rats. Pharmacol Biochem Behav 48(1): 111-118
17. Danysz W, Parsons CG, Bresink I, Quack G (1995) Glutamate in CNS disorders - a revived target for drug development? Drug News Perspects 8:261-277
18. B antagonists as potential therapeutic agents. Amino Acids 14:235-240
19. Debono MW, Le Gruen J, Canton T, Doble A, Pradier L (1993) Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes. Eur J Pharmacol 235:283-289
20. Diener HC, Hacke W, Hennerici M, Radberg J, Hantson L, De Keyser J (1996) Lubeluzole in acute ischemic stroke, a double-blind, placebo-controlled phase II trial. Lubeluzole International Study Group. Stroke 27:76-81
21. Doble A (1996) The pharmacology and mechanism of action of riluzole. Neurology 47:S233-S241
22. Grotta J, Clark W, Coull B, Pettigrew LC, Mackay B, Goldstein LB, Meissner I, Murphy D, LaRue L (1995) Safety and tolerability of the glutamate antagonist CGS 19755 (selfotel) in patients with acute ischemic stroke. Stroke 26:602-605
23. Hauber W, Andersen R (1993) The non-NMDA glutamate receptor antagonist GYKI 52466 counteracts locomotor stimulation and anticataleptic activity induced by the NMDA antagonist dizocilpine. Naunyn Schmiedebergs Arch Pharmacol 348:486-490
24. Hauber W, Waldenmeier MT (1994) The AMPA receptor antagonist GYKI 52466 reverses the anti-cataleptic effects of the competitive NMDA receptor antagonist CGP 37849. Eur J Pharmacol 256:339-342
25. Hebert T, Drapeau P, Pradier L, Dunn RJ (1994) Block of the rat brain IIA sodium channel α subunit by the neuroprotective drug riluzole. Mol Pharmacol 45:1055-1060
26. Hubert JP, Doble A (1989) Ibotenic acid stimulated D-[3H]-aspartate release from cultured cerebellar granule cells. Neurosci Lett 96:345-350
27. Johnson KM, Jones SM (1990) Neuropharmacology of phencyclidine: basic mechanisms and therapeutic potential. Annu Rev Pharmacol Toxicol 30:707-750
28. Kretschmer BD (1994) Felbamate, an anti-convulsive drug, has anti-parkinsonian potenial in rats. Neurosci Lett 179:115-118
29. Kretschmer BD (1998) Ligands of the NMDA receptor-associated glycine recognition site and motor behavior. Amino Acids 14:227-234
30. Kretschmer BD, Schmidt WJ (1996) Behavioral effects mediated by the modulatory glycine site of the NMDA receptor in the anterodorsal striatum and nucleus accumbens. J Neurosci 16:1561-1569
31. Kretschmer BD, Zadow B, Volz TL, Volz L, Schmidt WJ (1992) The contribution of the different binding sites of the N-methyl-D-aspartate (NMDA) receptor to the expression of behavior. J Neural Transm 87:23-35
32. Kretschmer BD, Winterscheid B, Danysz W, Schmidt WJ (1994) Glycine site antagonists abolish dopamine D2 but not D1 receptor mediated catalepsy in rats. J Neural Transm 95:123-136
33. Kretschmer BD, Kratzer U, Breithecker K, Koch M (1997). ACEA 1021, a glycine site antagonist with minor psychotomimetic and amnestic side effects in rats. Eur J Pharmacol 331:109-116
34. Kristensen JD, Svensson B, Gordh T (1992) The NMDA-receptor antagonist CPP abolishes neurogenic ëwind-up pain' after intrathecal administration in humans. Pain 51:249-253
35. Lacomblez I., Benismon G, Leigh PN, Guillet P, Meininger V (1996) Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 347: 1425-1431
36. Lowe DA, Emrc M, Frey P, Kelly PH, Malanowski J, McAllister KH, Neijt HC, Rudeberg C, Urwyler S, White TG, Herrling PL (1994) The pharmacology of SDZ EAA 494, a competitive NMDA antagonist. Neurochem Int 25:583-600
37. Luby ED, Gottlieb JS, Cohen BD, Rosenbaum G, Domino EF (1962) Model psychoses and schizophrenia. Am J Psychiatry 119:61-67
38. Maj J, Skuza G, Rogoz Z (1993) Some central effects of CGP 37849 and CGP 39551, the competitive NMDA receptor antagonists: potential antiparkinsionan activity. J Neural Transm 6:53-62
39. Mantz, J (1996) Riluzole. CNS Drug Rev 2:40-51
40. Mantz J, Laudenbach V, Lecharny JB, Henzel D, Desmonts JM (1994) Riluzole, a novel antiglutamate, blocks GABA uptake by striatal synaptosomes. Eur J Pharmacol 257:R7-R8
41. McAllister KH (1996) The competitive NMDA receptor antagonist SDZ 220-581 reverses haloperidol-induced catalepsy in rats. Eur J Pharmacol 314:307-311
42. Muir KW, Lees KR (1995) Clinical experience with excitatory amino acid antagonist drugs. Stroke 26:503-513
43. Muir KW, Grosset DG, Gamzu E, Lees KR (1994) Pharmacological effects of the non-competitive NMDA antagonist CNS 1102 in normal volunteers. Br J Clin Pharmacol 38:33-38
44. Papa SM, Engber TM, Boldry RC, Chase TN (1993) Opposite effects of NMDA and AMPA receptor blockade on catalepsy induced by dopamine receptor antagonists. Eur J Pharmacol 232:247-253
45. Parada-Turska J, Turski WA (1990) Excitatory amino acid antagonists and memory: effect of drugs acting at N-methyl-D-aspartate receptors in learning and memory tasks. Neuropharmacology 29:1111-1116
46. Rockstroh S, Emre M, Tarral A, Pokorny R (1996) Effects of the novel NMDA receptor antagonist SDZ EAA 494 on memory and attention in humans. Psychopharmacology 124:261-266
47. Scheel-Krüger J, Arnt J, Magelund G, Olianas M, Przewlocka B, Christensen AV (1980) Behavioural functions of GABA in basal ganglia and limbic system. Brain Res Bull 5(S2):261-267
48. Schmidt WJ (1986) Intrastriatal injection of DL-2-amino-5-phosphonovaleric acid (AP-5) induces sniffing stereotypy that is antagonized by haloperidol and clozapine. Psychopharmacology 90:123-130
49. Schmidt WJ, Bubser M (1989) Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in rats. Pharmacol Biochem Behav 32:621-623
50. Schmidt WJ, Zadow B, Kretschmer BD, Hauber W (1991) Anticataleptic potencies of glutamate-antagonists. Amino Acids 1:225-237
51. Shreve PE, Uretsky NJ (1988) Role of quisqualic acid receptors in the hypermotility response produced by the injection of AMPA into the nucleus accumbens. Pharmacol Biochem Behav 30:379-384
52. Svensson A, Pileblad E, Carlsson M (1991) A comparison between the non-competitive NMDA antagonist dizocilpine (MK-801) and the competitive NMDA antagonist D-CPPene with regard to dopamine turnover and locomotor-stimulatory properties in mice. J Neural Transm 85:117-159
53. Tiedtke PI Bischoff C, Schmidt WJ (1990) MK-801-induced stereotypy and its antagonism by neuroleptic drugs. J Neural Transm 81:173-182
54. Verma A, Kulkarni SK (1992) D1/D2 dopamine and N-methyl-D-aspartale (NMDA) receptor participation in experimantal catalepsy in rats. Psychopharmacology 109:477-483
55. Wan F-J, Swerdlow NR (1996) Sensorimotor gating in rats is regulated by different dopamine-glutamate interactions in the nucleus accumbens core and shell subregions. Brain Res 722:168-176
56. Zadow B, Schmidt WJ (1994) The AMPA antagonists NBQX and GYKI 52466 do not counteract neuroleptic-induced catalepsy. Naunyn Schmiedebergs Arch Pharmacol 349:61-65